

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <b>MIDDLETON FRED A</b>  (Last) (First) (Middle) <b>C/O CALCIMEDICA, INC.</b> <b>505 COAST BLVD. S. #307</b>  (Street) <b>LA JOLLA CA 92037</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>CalciMedica, Inc. [ CALC ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>01/23/2024</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/23/2024		p <sup>(1)</sup>		243,356	A	\$3.702	946,744	I	By Sanderling Venture Partners VI, LP <sup>(2)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		144,676	A	\$3.702	727,433	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P. <sup>(3)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		194,472	A	\$3.702	435,148	I	By Sanderling Ventures VII, L.P. <sup>(4)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		51,032	A	\$3.702	114,260	I	By Sanderling Ventures VII (Canada), L.P. <sup>(5)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		13,184	A	\$3.702	27,609	I	By Sanderling Ventures VII Annex Fund, L.P. <sup>(4)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		3,920	A	\$3.702	21,602	I	By Sanderling Ventures Management VI <sup>(3)</sup>
Common Stock	01/23/2024		p <sup>(1)</sup>		28,744	A	\$3.702	30,292	I	By Sanderling Ventures Management VII <sup>(5)</sup>
Common Stock								11,714	D	
Common Stock								8,176	I	By Golden Triangle Ventures, LLC <sup>(6)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--------------------------------------------	--------------------------------------------------------	--------------------------------------	----------------------------------------------------	--------------------------------	----------------------------------------------------------------------------------------	----------------------------------------------------------	-----------------------------------------------------------------------------------	--------------------------------------------	--------------------------------------------------------------------------	-----------------------------------------------------------	--------------------------------------------------------



7. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

8. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

/s/ John Dunn, Attorney-in-Fact 01/25/2024

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**